BridgeMD
New treatment option for Relapsed or Refractory Hematologic Malignancies
Official title Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
ClinicalTrials.gov ID: NCT03838926
What this study is testing
What is Trichostatin A?
Trichostatin A is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for relapsed or refractory hematologic malignancies.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Subject is ≥ 18 years at the time of signing informed consent;
- Confirmed malignant hematologic disease or lymphoid malignancy that has relapsed or is refractory to standard therapy and has exhausted all available...
- Presence of measurable or evaluable disease;
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2;
- Contraceptives or other approved avoidance of pregnancy measures
You likely can't join if
- Allogeneic stem cell transplant recipient presenting with graft versus host disease (GVHD) either active or requiring immunosuppression;
- Concomitantly taking anti-cancer therapy (bisphosphonates are permitted);
- Undergone major surgery ≤ 2 weeks prior to starting study drug;
- Evidence of mucosal or internal bleeding;
- Impaired cardiac function or conduction defect;
- Concurrent severe and/or uncontrolled medical conditions
The study team makes the final eligibility decision.
Where it's taking place
- Washington D.C., District of Columbia, United States
- Lafayette, Indiana, United States
- Hackensack, New Jersey, United States
- Seattle, Washington, United States
- Biała Podlaska, Poland
- Katowice, Poland
- Krakow, Poland
- Opole, Poland
- Skorzewo, Poland
- Warsaw, Poland
- Wroclaw, Poland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Washington D.C., District of Columbia, United States; Lafayette, Indiana, United States; Hackensack, New Jersey, United States; Seattle, Washington, United States; Biała Podlaska, Poland; Katowice, Poland and 5 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.